Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Benzinga02-10 01:59

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK). The Japanese drug maker will use Iambic's AI ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610065027?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/09/Takeda-Pharma-Photo-by-Veroniksha-via-Sh.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-02-10 01:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610065027","market":"sh","top_or_hot":-1,"title":"Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery","media":"Benzinga","content":"<div>\n<p>AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK).\nThe Japanese drug maker will use Iambic's AI ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50489158/takeda-taps-ai-startup-iambic-in-1-7-billion-deal-to-speed-up-drug-discovery\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 01:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50489158/takeda-taps-ai-startup-iambic-in-1-7-billion-deal-to-speed-up-drug-discovery><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK).\nThe Japanese drug maker will use Iambic's AI ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50489158/takeda-taps-ai-startup-iambic-in-1-7-billion-deal-to-speed-up-drug-discovery\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4543","symbol_name":"AI","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50489158/takeda-taps-ai-startup-iambic-in-1-7-billion-deal-to-speed-up-drug-discovery","article_id":"2610065027","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/09/Takeda-Pharma-Photo-by-Veroniksha-via-Sh.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50489158/takeda-taps-ai-startup-iambic-in-1-7-billion-deal-to-speed-up-drug-discovery","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610065027","pubTimestamp":1770659940,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited .The Japanese drug maker will use Iambic's AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda's oncology, gastrointestinal, and inflammation therapeutic areas.Through the agreement, Takeda will also gain access to NeuralPLexer, Iambic's model for predicting protein-ligand complexes.Based in San Diego and founded in 2020, Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform.\"Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates,\" said Tom Miller, Co-Founder and CEO of Iambic.\"Iambic's small molecule platform aligns with this ambition and offer","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4543":"AI","BK4007":"制药","BK4551":"寇图资本持仓","TAK":"武田制药","BK4587":"ChatGPT概念","BK4528":"SaaS概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AI":"C3.ai, Inc."},"translate_title":"武田以超过17亿美元的交易收购人工智能初创公司Iambic，以加速药物发现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1,"AI":0.9},"content_text":"AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK).\nThe Japanese drug maker will use Iambic's AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda's oncology, gastrointestinal, and inflammation therapeutic areas.\nThrough the agreement, Takeda will also gain access to NeuralPLexer, Iambic's model for predicting protein-ligand complexes.\nBased in San Diego and founded in 2020, Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform.\n\"Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates,\" said Tom Miller, Co-Founder and CEO of Iambic.\n\"Iambic's small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve probability of success, and more quickly advance select programs from early project start to IND,\" Chris Arendt, Chief Scientific Officer and Head of Research at Takeda.\nUnder the terms of the agreement, Iambic will receive upfront, research cost, and technology access payments and is eligible to receive success-based payments that could exceed $1.7 billion.\nThe company is also eligible to receive royalties on net sales of any products generated from this collaboration.\nThe collaboration will utilize Iambic's AI models as well as the company's fully integrated, high-throughput, and automated wet lab capabilities.\nThese core capabilities support a rapid Design-Make-Test-Analyze cycle that can accelerate program advancement.\nReuters reported that drug developers are increasingly turning to AI technologies to speed up discovery and cut costs, with experts predicting timelines could be halved in the coming years.\nTraditional drug discovery can take around six years before a compound reaches clinical trials, Iambic Chief Executive Tom Miller told Reuters.\nIambic said its approach, combining AI predictions with automated laboratories, can compress that timeline to less than two years.\nTakeda Chief Scientific Officer Christopher Arendt said the technology could significantly shorten research timelines, though speed is only part of the appeal.\n\"When you start to add an AI engine to your small‑molecule drug development, it means you can go faster,\" Reuters noted, citing Arendt's interview, adding that molecular quality is equally critical.\nTAK Price Action: Takeda Pharmaceutical Co shares were down 1.26% at $17.66 at the time of publication on Monday. The stock is approaching its 52-week high of $17.98, according to Benzinga Pro data.\nPhoto by Veroniksha via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610065027","isCrawlerRequest":true}